HIPEC Consensus Statement

In October 2006, a consensus statement from the Peritoneal Surface Malignancy Group (PSMG), a group of 72 leading national and international surgical oncologists from 55 cancer centers in 14 countries, including the United States, was published in the Annals of Surgical Oncology. The group concluded that surgery followed by heated chemotherapy delivered through the lower abdomen of the patient, may significantly increase the life expectancy for patients with Stage IV colorectal cancer.

Click here to view the HIPEC Consensus Statement (PDF).

Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.

Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study.

Gastric perforation following cytoreductive surgery with perioperative intraperitoneal chemotherapy.

In vivo Toxicity and Bioavailability of Taxol((R)) and a Paclitaxel/beta-Cyclodextrin Formulation in a Rat Model During HIPEC.

Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.

Peritoneal-based malignancies and their treatment.

[Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer]

Peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian peritoneal carcinomatosis: an argued role.

Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer.

Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.

Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence.

The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer.

Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.

The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

Establishing evidence for change in ovarian cancer surgery--proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis.

Cytoreductive surgery (cs) and hyperthermic intraperitoneal chemotherapy (hipec) in treatment of peritoneal surface malignances: report of a phase II clinical study.

Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.

Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.

Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.

(18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study.

Peritonectomy for peritoneal carcinomatosis: long-term outcomes from a single Brazilian institution.

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.

Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece.

Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.

Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis.

Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.

Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.

[Updated treatment of peritoneal carcinomas: a review]

Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.

Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis.

Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.

Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.

Pharmacodynamic aspects of intraperitoneal cytotoxic therapy.

Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients.

Hemodynamic and cardiovascular problems during modified hyperthermic intraperitoneal perioperative chemotherapy.

[Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy]

Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy.

Peritoneal Surface Oncology: A progress report.

Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: an experimental study.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer.